Literature DB >> 28421464

A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma.

Daniel Bulzico1,2, Davi Coe Torres3, Gerson Moura Ferreira4, Bruno Ricardo Barreto Pires4, Paulo Antônio Silvestre de Faria5, Rocio Hassan3, Eliana Abdelhay4, Mario Vaisman6, Leonardo Vieira Neto7,6.   

Abstract

Adrenocortical carcinomas (ACC) are very rare tumors related to TP53 mutations mostly in childhood onset cases. Epithelial-mesenchymal transition (EMT) transcription factors TWIST1 and Smad interacting protein 1 (SIP1) are related to poorer outcomes in other malignancies, but their role in ACC is unknown. We describe a case of an advanced metastatic ACC (Weiss-score of 9) in a patient at age 76. After primary tumor resection, mitotane therapy was started as palliation to low-volume liver metastasis. After a 2-year period of stable disease, the patient died due to brain metastasis. Somatic gene sequencing revealed a novel TP53 mutation in DNA extracted from paraffin-embedded tissue, a deletion of 8bp in exon 8 (c.811_818del8; GAGGTGCG/-) in homo or hemizygosis causing a subsequent frameshift and premature stop codon at position 302. Immunohistochemistry of P53 and p-Ser-15 P53 showed absent tumoral staining. In addition, immunohistochemical analysis showed an increased expression of the mesenchymal markers vimentin and fibronectin. At last, EMT transcription factors TWIST1 and SIP1 were also overexpressed in tumoral cells. This case report describes an aggressive ACC with not only a novel somatic mutation, but also a novel International Agency for Research on Cancer database 8 base-pair deletion in TP53 exon 8. In addition, the expression of EMT inducers TWIST1 and SIP1 have been reported for the first time in an ACC case. Further investigation is needed to clarify the biologic significance of this new TP53 mutation and its role in the EMT process.

Entities:  

Keywords:  Adrenocortical carcinoma; Mutation; SIP1; TP53; TWIST1

Mesh:

Substances:

Year:  2017        PMID: 28421464     DOI: 10.1007/s12022-017-9482-7

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  40 in total

1.  Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

Authors:  Jonathan D Wasserman; Ana Novokmet; Claudia Eichler-Jonsson; Raul C Ribeiro; Carlos Rodriguez-Galindo; Gerard P Zambetti; David Malkin
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

2.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.

Authors:  Frédérique Tissier; Catherine Cavard; Lionel Groussin; Karine Perlemoine; Gwladys Fumey; Anne-Marie Hagneré; Fernande René-Corail; Eric Jullian; Christine Gicquel; Xavier Bertagna; Marie-Cécile Vacher-Lavenu; Christine Perret; Jérôme Bertherat
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

3.  Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.

Authors:  L Barzon; M Chilosi; F Fallo; G Martignoni; L Montagna; G Palù; M Boscaro
Journal:  Eur J Endocrinol       Date:  2001-08       Impact factor: 6.664

4.  Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer.

Authors:  Zhang Yan-Qi; Guo Xue-Yan; Han Shuang; Chen Yu; Ge Fu-Lin; Bai Fei-Hu; Sun Shi-Ren; Wei Xu-Feng; Ding Jie; Fan Dai-Ming
Journal:  Pathology       Date:  2007-10       Impact factor: 5.306

5.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.

Authors:  M Reincke; M Karl; W H Travis; G Mastorakos; B Allolio; H M Linehan; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.

Authors:  Victoria M Raymond; Tobias Else; Jessica N Everett; Jessica M Long; Stephen B Gruber; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2012-11-21       Impact factor: 5.958

8.  SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions.

Authors:  Cindy Vandewalle; Joke Comijn; Bram De Craene; Petra Vermassen; Erik Bruyneel; Henriette Andersen; Eugene Tulchinsky; Frans Van Roy; Geert Berx
Journal:  Nucleic Acids Res       Date:  2005-11-24       Impact factor: 16.971

9.  Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.

Authors:  Aude Salomon; Michelle Keramidas; Cécile Maisin; Michaël Thomas
Journal:  Oncotarget       Date:  2015-05-10

10.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

View more
  5 in total

1.  High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1.

Authors:  Bing Hu; Xin Li; Ling Chen; Zhongliang Liu
Journal:  Lung       Date:  2020-02-07       Impact factor: 2.584

2.  Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?

Authors:  Daniel Bulzico; Paulo Antônio Silvestre de Faria; Camila Bravo Maia; Marcela Pessoa de Paula; Davi Coe Torres; Gerson Moura Ferreira; Bruno Ricardo Barreto Pires; Rocio Hassan; Eliana Abdelhay; Mario Vaisman; Leonardo Vieira Neto
Journal:  Endocrine       Date:  2017-09-08       Impact factor: 3.633

Review 3.  Genetic And Epigenetic Regulation Of E-Cadherin Signaling In Human Hepatocellular Carcinoma.

Authors:  Xiaoxiao Fan; Shengxi Jin; Yirun Li; Parikshit Asutosh Khadaroo; Yili Dai; Lifeng He; Daizhan Zhou; Hui Lin
Journal:  Cancer Manag Res       Date:  2019-10-16       Impact factor: 3.989

4.  The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.

Authors:  Guangyu Wang; Dandan Xu; Zicheng Zhang; Xinhui Li; Jiaqi Shi; Jie Sun; Huan-Zhong Liu; Xiaobo Li; Meng Zhou; Tongsen Zheng
Journal:  NPJ Precis Oncol       Date:  2021-06-22

5.  Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.

Authors:  Jiayu Liang; Zhihong Liu; Xin Wei; Liang Zhou; Yongquan Tang; Chuan Zhou; Kan Wu; Fuxun Zhang; Fan Zhang; Yiping Lu; Yuchun Zhu
Journal:  BMC Cancer       Date:  2019-11-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.